Related Experiment Video
Updated: May 11, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Prima-1 induces apoptosis in bladder cancer cell lines by activating p53
Camila B Piantino1, Sabrina T Reis, Nayara I Viana
1Laboratory of Medical Investigation, Urology Department - LIM55, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. camilapiantino@hotmail.com
Objectives:
Bladder cancer represents 3% of all carcinomas in the Brazilian population and ranks second in incidence among urological tumors, after prostate cancer. The loss of p53 function is the main genetic alteration related to the development of high-grade muscle-invasive disease. Prima-1 is a small molecule that restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Our aim was to investigate the ability of Prima-1 to induce apoptosis after DNA damage in bladder cancer cell lines.
Method:
The therapeutic effect of Prima-1 was studied in two bladder cancer cell lines: T24, which is characterized by a p53 mutation, and RT4, which is the wild-type for the p53 gene. Morphological features of apoptosis induced by p53, including mitochondrial membrane potential changes and the expression of thirteen genes involved in apoptosis, were assessed by microscopic observation and quantitative real-time PCR (qRT-PCR).
Results:
Prima-1 was able to reactivate p53 function in the T24 (p53 mt) bladder cancer cell line and promote apoptosis via the induction of Bax and Puma expression, activation of the caspase cascade and disruption of the mitochondrial membrane in a BAK-independent manner.
Conclusion:
Prima-1 is able to restore the transcriptional activity of p53. Experimental studies in vivo may be conducted to test this molecule as a new therapeutic agent for urothelial carcinomas of the bladder, which characteristically harbor p53 mutations.
Insights
Prima-1 reactivates tumor suppressor p53 function in bladder cancer cells with p53 mutations, inducing apoptosis. This suggests Prima-1 as a potential therapeutic agent for urothelial carcinomas.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Bladder cancer is a common carcinoma, with high-grade muscle-invasive disease often linked to p53 gene mutations.
- The p53 protein is a crucial tumor suppressor, and its loss of function is a key event in cancer development.
- Prima-1 is a novel small molecule designed to restore the function of mutant p53.
Purpose of the Study:
- To investigate the efficacy of Prima-1 in inducing apoptosis in bladder cancer cell lines.
- To determine if Prima-1 can restore p53 function and promote cancer cell death.
Main Methods:
- Two bladder cancer cell lines (T24 with p53 mutation, RT4 with wild-type p53) were treated with Prima-1.
- Apoptosis was assessed by evaluating morphological changes, mitochondrial membrane potential, and the expression of apoptosis-related genes using quantitative real-time PCR (qRT-PCR).
Main Results:
- Prima-1 reactivated p53 in the T24 cell line (p53 mutation).
- Apoptosis was induced through increased Bax and Puma expression, caspase cascade activation, and mitochondrial membrane disruption.
- The apoptotic process occurred in a BAK-independent manner.
Conclusions:
- Prima-1 successfully restored the transcriptional activity of p53 in bladder cancer cells.
- Prima-1 shows promise as a potential therapeutic agent for urothelial carcinomas, particularly those with p53 mutations.
- Further in vivo studies are warranted to evaluate Prima-1 as a novel therapeutic strategy.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
